BCX 4430

• CAT Number: I002705
• CAS Number: 222631-44-9
• Molecular Formula: C11H16ClN5O3
• Molecular Weight: 301.73
• Purity: ≥95%
• Target: Anti-infection
• Solubility: H2O: ≥ 41 mg/mL
• Storage: Store at RT
• IUPAC Name: (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol;hydrochloride
• InChI: InChI=1S/C11H15N5O3.ClH/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7;/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15);1H/t5-,7+,9-,10+;/m1./s1
• InChIKey: PCCHVYNGFMEGIG-QPAIBFMUSA-N
• SMILES: C1=C(C2=C(N1)C(=NC=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O.Cl

BCX 4430（Cat No.:I002705）is an experimental antiviral drug developed by BioCryst Pharmaceuticals, primarily investigated for its potential in treating viral infections, including filoviruses (such as Ebola) and arenaviruses. It is a nucleoside analog that inhibits RNA-dependent RNA polymerase, an enzyme critical for viral replication. By disrupting the replication process, BCX 4430 shows promise in preventing the spread of viral infections. It has demonstrated activity in preclinical models against various viruses, and clinical trials have been conducted to assess its safety and efficacy. BCX 4430 represents a potential therapeutic option for treating emerging viral outbreaks.